Journal of Medicinal Chemistry · 2013 · 90 citations · 101 references
MedicineMedicinal ChemistryPharmacologyCell SignalingDrug DiscoveryMolecular PharmacologyLigand BindingReceptor PharmacologyReceptor Signaling In NeuronsSerotonergic PharmacologySerotonergic Signaling5-Hydroxytryptamine 1A Receptor AgonistsAgonist ActivitySerotonergic Drug DiscoverySerotonin Receptor PharmacologySerotonin Receptor SignalingSerotonin Receptor SubtypesSerotonin ReceptorsTherapeutic Uses
The serotonin receptor subtype 5-HT(1A) was one of the first serotonin receptor subtypes pharmacologically characterized. This receptor subtype has long been object of intense research and is implicated in the pathogenesis and treatment of anxiety and depressive disorders. In recent years, new chemical entities targeting the 5-HT(1A) receptor (alone or in combination with other molecular targets) have been proposed for novel therapeutic uses in neuroprotection, cognitive impairment, Parkinson's disease, pain treatment, malignant carcinoid syndrome, and prostate cancer. This Perspective compares existing data on expression and signaling activity of the 5-HT(1A) receptor to a ligand with an intrinsic agonist or antagonist profile. Our purpose is also to make a complete overview, useful for underlining the features needed to select a specific pharmacological profile rather than another one. This aspect could be really interesting to consider and justify the 5-HT(1A) receptor as a new attractive target for drug discovery.
101
Activation and Cleavage of Caspase-3 in Apoptosis Induced by Experimental Cerebral Ischemia
Shobu Namura, Jinmin Zhu, Klaus Fink et al. · Journal of Neuroscience · 1998 · 894 citations · Full text
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats
Manolo Carta, Thomas Carlsson, Deniz Kirik et al. · Brain · 2007 · 622 citations · Full text